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Viruses are frequent causes of respiratory infection, and viral respiratory infections are signiﬁcant causes of hospitalization,
morbidity, and sometimes mortality in a variety of patient populations. Lung inﬂammation induced by infection with
common respiratory pathogens such as inﬂuenza and respiratory syncytial virus is accompanied by increased lung production
of prostaglandins and leukotrienes, lipid mediators with a wide range of eﬀects on host immune function. Deﬁciency or
pharmacologic inhibition of prostaglandin and leukotriene production often results in a dampened inﬂammatory response to
acute infection with a respiratory virus. These mediators may, therefore, serve as appealing therapeutic targets for disease caused
by respiratory viral infection.
1. Respiratory Viruses
Viruses are the most frequent cause of respiratory infection
in humans. It has been estimated that viruses cause up to
90% of lower respiratory infection (LRI) hospitalizations in
children less than 5 years of age and up to 40% of hospi-
talizations in children age 5–18 years [1]. Among the most
common causes of viral respiratory infection in children
and adults are respiratory syncytial virus (RSV), inﬂuenza,
rhinovirus (RV), adenovirus, parainﬂuenza virus (PIV), and
human metapneumovirus (hMPV) [2]. Viral respiratory
infection also causes substantial disease burden in the elderly
and immunocompromised populations [3, 4].
The host immune system faces the task of eﬀectively
clearing a virus while limiting local tissue damage and
inﬂammation. The immune response to viruses can be
protective, aiding with clearance of virus from the lungs
and resolution of disease caused by viral replication. Disease
associated with respiratory viruses can also be caused by
immune-mediated pathology. Virus-induced inﬂammation
can be detrimental to the host, causing symptoms during
acute infection and leading to damage that contributes to
long-term residual lung disease. Eicosanoids are potent lipid
mediators that play a role in many biological processes,
including inﬂammation and immune function. Two classes
of eicosanoids, the prostaglandins (PGs) and leukotrienes
(LTs), have been increasingly studied in the context of respi-
ratoryviralinfection.Becauseoftheseeﬀects,eicosanoidsare
likely to make signiﬁcant contributions to the pathogenesis
of respiratory virus infection.
2. EicosanoidSynthesis
2.1. Prostaglandins. PGs are generated when phospholipase
A2 (PLA2) releases arachidonic acid (AA) from membrane
glycerophospholipids (Figure 1). Released AA is oxidized
to the intermediate prostaglandin H2 (PGH2)b yc y c l o o x y -
genase (COX). COX exists in three isoforms. COX-1 is
generally constitutively expressed, while COX-2 expression is
rapidly induced by growth factors and cytokines [5]. COX-
3 is a recently discovered isoform whose biological role, if
any, remains poorly understood [6, 7]. Once formed, PGH2
can be converted by speciﬁc synthases to thromboxane A2
(TXA2), PGD2,P G E 2,P G F 2,a n dP G I 2.A sd e s c r i b e db e l o w ,
PGE2 has multiple eﬀects on host immune function. PGE2
is transported from the cell by multidrug resistance protein2 Mediators of Inﬂammation
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Figure 1: Synthesis of PGE2 and the leukotrienes. cPLA2—cytosolic phospholipase A2, AA—arachidonic acid, FLAP—5-lipoxygenase
activating protein, 5-LO—5-lipoxygenase, LTA4—leukotriene A4,L T A 4H—leukotriene A4 hydrolase, LTB4— leukotriene B4,B L T 1a n d
BLT2—B leukotriene receptor 1 and 2, LTC4S—leukotriene C4 synthase, LTC4—leukotriene C4, γ-GT-γ-glutamyl transpeptidase, γ-GL-
γ-glutamyl leukotrienease, LTD4—leukotriene D4, DiP—dipeptidase, LTE4—leukotriene E4, cysLTs—cysteinyl leukotrienes, cysLT1 and
cysLT2—cysteinyl leukotriene receptor 1 and 2, COX-1 and COX-2—cyclooxygenase 1 and 2, PGH2—prostaglandin H2, mPGES-1 and
-2—microsomal prostaglandin E synthase-1 and -2, PGE2—prostaglandin E2, EP1-4—E prostanoid receptors 1–4.
(MRP) 4 and possibly by other unknown transporters [8].
The eﬀects of PGE2 are mediated by its signaling through
four distinct G protein-coupled E prostanoid (EP) receptors,
EP1-4. The EP1 receptor is coupled to an unidentiﬁed G
proteinandmediatesPGE2-inducedincreasesinintracellular
Ca2+ [9]. The EP2 and EP4 receptors mediate increases in
cyclic AMP (cAMP) concentration by coupling to Gαs.F o u r
isoforms of the EP3 receptor are coupled to diﬀerent G
proteins, although the major EP3 receptor signaling pathway
involves adenylate cyclase inhibition via Gαi coupling with
subsequent decreases in intracellular cAMP [10]. The EP2
and EP4 receptors are expressed in almost all mouse tissues,
while expression of EP1 is restricted to several organs,
including the lung. EP2 expression is the least abundant of
the EP receptors, however, several stimuli induce expression
of EP2 [10].
2.2. Leukotrienes. LTs are also generated by liberation of
AA from cell membranes (Figure 1). This is modiﬁed by
a series of enzymes beginning with 5-lipoxygenase (5-
LO), which acts in concert with 5-LO-activating protein
(FLAP) to form leukotriene A4 (LTA4)[ 11]. LTA4 can then
be metabolized by LTA4 hydrolase to form leukotriene B4
(LTB4). Alternatively, LTA4 can be conjugated to reduced
glutathione by leukotriene C4 (LTC4) synthase to form LTC4.
LTC4 is exported from the cell by speciﬁc transporters [12]
and can be acted on by extracellular peptidases to form LTD4
or LTE4. Leukotrienes C4,D 4,o rE 4 are collectively known as
the cysteinyl leukotrienes (cysLTs).
Expression of 5-LO is tightly regulated and is primarily
restricted to cells of the myeloid lineage, such as mono-
cytes/macrophages, mast cells, eosinophils, and neutrophils.
Although LT synthesis was once thought to be restricted
to leukocytes, it has subsequently been shown that human
bronchial epithelial cells and ﬁbroblasts are capable of
producing both cysLTs and LTB4 [13, 14]. In addition, the
intermediate LTA4 can be transferred from an activated
donor cell to a recipient cell. LTA4 can then be metabolized
to either LTB4 or LTC4 by LTA4 hydrolase or LTC4 synthase,
respectively, in a process termed “transcellular biosynthesis”
[15]. These enzymes are expressed in most tissues. In this
way, other cell types, such as epithelial cells, can become an
important source of LTs during an inﬂammatory response.
Like PGE2, the eﬀects of LTs are mediated by signaling
through G protein-coupled receptors. Among the receptors
for cysLTs, two have been thoroughly characterized. The
cysLT1 receptor binds LTD4 with high aﬃnity and binds
LTC4 andLTE4 withloweraﬃnities[16].ThecysLT2receptor
binds LTC4 and LTD4 with equal aﬃnity. A number of
studies have alluded to the existence of additional cysLTR
subtypes, although these have yet to be characterized [17].
The chemoattractant and proinﬂammatory eﬀects of LTB4
are mediated by the high-aﬃnity B leukotriene receptor 1
(BLT1). A second receptor, B leukotriene receptor 2 (BLT2),
binds LTB4 with lower aﬃnity, but its biological function
remains poorly understood [18]. Studies in transfected cell
lines have shown that the four LT receptors can couple to
both Gαi and Gαq proteins to decrease cAMP and increase
intracellular Ca2+,r e s p e c t i v e l y[ 19–23]. Studies in primary
cells have yielded diﬀering results and the speciﬁc signaling
programs initiated by GPCRs remain to be dissected [24].
Within the human lung, cysLT1 mRNA is expressed in
epithelial cells, bronchial smooth muscle cells, interstitial
macrophages, and the nasal mucosa. CysLT2 is expressed
by bronchial smooth muscle cells, interstitial macrophages,
and nasal mucosa [17]. Human BLT1 is expressed primarily
in leukocytes and its expression can be altered in response
to various inﬂammatory stimuli [18, 25]. BLT2 is expressedMediators of Inﬂammation 3
more ubiquitously, with high mRNA expression detected in
the spleen and low levels in most human tissues, including
the lung [26].
3. Eicosanoids andImmune Function
3.1. Prostaglandin E2. PGE2 regulates immune function in
a myriad of ways that are likely to aﬀect viral pathogen-
esis (Table 1). Widespread expression of COX-2 has been
demonstratedin airwayepithelial andresidentinﬂammatory
cells in the absence of overt inﬂammation, suggesting a role
for COX-2 in regulation of human airway homeostasis [27].
High concentrations of COX products are present in the
epithelial lining ﬂuid of human airways, potentially playing
a role in inhibiting lymphocyte activity and ﬁbroblast pro-
liferation in the absence of inﬂammation [28]. Additionally,
constitutive secretion of PGE2 by airway epithelial cells con-
tributestomodulationofDCsunderhomeostaticconditions
[29]. PGE2 can promote inﬂammation through vasodilatory
mechanisms,yieldingedema,warmth,erythema,andpassive
leukocyte recruitment. However, PGE2 is also capable of
inhibiting neutrophil chemotaxis, phagocytosis, and bacte-
rial killing [30, 31]. PGE2 suppresses phagocytosis by non-
alveolarmonocytes/macrophages[32–35],andPGE2 inhibits
alveolar macrophage (AM) phagocytosis via a mechanism
that involves EP2 activation and increases in cAMP [36].
Bacterial killing and reactive oxygen intermediate generation
by AMs is also inhibited by PGE2 in an EP2/EP4- and cAMP-
dependent manner [37].
The production of various pro-inﬂammatory cytokines
and chemokines is inhibited in the presence of PGE2 [38,
39], while production of the anti-inﬂammatory cytokine
interleukin (IL)-10 is enhanced [40]. PGE2 suppresses pro-
duction of the Th1 cytokines interferon (IFN)-γ and IL-12,
leading to a Th2-polarized environment [41, 42]. However,
a number of studies have also reported PGE2-mediated
enhancement of Th1 cytokine secretion and diﬀerentiation
in vivo [43, 44] .T h er o l eo fP G E 2 is not strictly suppressive,
as it has been shown to promote certain pathways in
immune diﬀerentiation. For example, PGE2 can act on
uncommitted B lymphocytes to promote isotype switching
t oI g Eo rI g G 1[ 45–47]. COX inhibitors inhibit antibody
production in activated human B lymphocytes [48, 49].
PGE2 augments IL-17 production and Th17 diﬀerentiation
by increasing IL-23 production in T cells and dendritic cells
[44, 50–53], an activity that likely occurs via EP2- and EP4-
mediated increases in cAMP [54, 55]. Additionally, PGE2
enhances the production of the proinﬂammatory cytokine
IL-6 by leukocytes [56] and airway epithelial cells [57].
PGE2 potently inhibits the production of a number of
antimicrobial peptides (AMPs) such as human β-defensin
by epithelial cells [58]. This eﬀect of PGE2 is likely to be
relevant for viral pathogenesis, because AMPs can inhibit the
replication of viruses [59, 60].
3.2. Leukotrienes. The diverse eﬀects of LTs on innate immu-
nity have been reviewed elsewhere [61]a n da r eb r i e ﬂ ys u m -
marizedinTable 1.L TB 4 promotesneutrophil migration and
survival [62, 63] and enhances neutrophil granule enzyme
secretion [64] and superoxide anion generation [65, 66].
T lymphocyte recruitment to sites of inﬂammation can be
induced by LTB4 [67–70]. In addition to neutrophil and T
cell traﬃcking, LTB4 can promote the migration of dendritic
cells (DCs) in vitro [71] and to draining lymph nodes as
mice deﬁcient in BLT1/2 show reduced DC migration [72].
Both cysLTs and LTB4 can enhance Fcγ receptor-mediated
phagocytosis by AMs, though by diﬀerent mechanisms
[24, 73, 74]. LTB4 induces antimicrobial peptide release
from neutrophils in vivo, in some cases inhibiting viral
replication[75–77].Lunggenerationoftheproinﬂammatory
cytokine TNF-α is enhanced by LTB4 [78]. A number of
studies have reported that LTB4 acts synergistically with
IL-4 to induce activation, proliferation, and diﬀerentiation
of human B lymphocytes [79–81], although a separate
study reported that 5-LO inhibitors actually enhanced B
lymphocyte proliferation [82].
CysLTs can promote microvascular leak [11], enhance
leukocyte survival [83, 84], and induce nitric oxide (NO)
generation in neutrophils [66, 85]. CysLTs induce DC
chemotaxis to CCL19 and DC traﬃcking to lymph nodes
is impaired in LTC4 transporter-deﬁcient mice [12]. In
addition, cysLTs have been suggested to play a role in
allergen-induced DC migration from blood [86]. Addition
of LTD4 to activated B lymphocytes leads to a modest
upregulation of IgE and IgG production [87]. CysLTs also
playaroleinregulationofapulmonaryTh2responseasmice
deﬁcient in LTC4 synthase showed reduced Th2 cytokine
mRNA expression and Ag-speciﬁc IgE and IgG1 in the lung
[88]. CysLTs are recognized as important mediators in the
pathogenesis of asthma by their ability to promote airway
microvascular permeability, mucus secretion, and smooth
muscle contraction [89–93].
The prostaglandins and leukotrienes modulate many
host immune responses that are important contributors to
viralpathogenesis,suchascytokinesignaling,neutrophiland
macrophage phagocytosis, traﬃcking and activation of DCs
and T cells, and antibody production by B cells.
4. EicosanoidsandRespiratory Viruses
4.1. Inﬂuenza. Inﬂuenza infections account for over 200,000
hospitalizations annually in the USA [94]. In addition
to hospitalizations, inﬂuenza is also associated with a
substantial number of outpatient visits each year, caus-
ing considerable healthcare burden and economic costs.
Inﬂuenza upregulates COX-2 expression both in vitro and
in vivo, and it has been suggested that COX hyperinduction
contributes to the exaggerated cytokine response observed
in severe human H5N1 infections [95–97]. Alteration of
the COX pathway has contrasting eﬀects on inﬂammatory
responses to inﬂuenza virus depending on the model of
pharmacologic inhibition (COX-1- or COX-2-speciﬁc or
dual inhibition) or of genetic deﬁciency. Treatment of
inﬂuenza-infected mice with celecoxib, a selective COX-2
inhibitor, did not signiﬁcantly aﬀect viral titers or disease
severity, although treatment did suppress production in
the lung of the proinﬂammatory cytokines tumor necrosis
factor- (TNF-) α, IL-6 and granulocyte-colony stimulating4 Mediators of Inﬂammation
Table 1: Eﬀects of PGE2 and leukotrienes on immune function.
PGE2 LTB4 cysLTs
Neutrophils
Inhibits neutrophil
chemotaxis, phagocytosis, and
bacterial killing
Promotes neutrophil
chemotaxis, ROS
generation, and survival
Induces NO generation in
neutrophils
Macrophages
Inhibits AM phagocytosis,
ROS generation, and bacterial
killing
Enhances AM phagocytosis Enhance AM phagocytosis
T cells Promotes Th17 diﬀerentiation Induces T cell recruitment Enhances Th2 response
B cells/Antibody
Production
Promotes isotype switching to
IgE and IgG1
Induces activation,
diﬀerentiation, and
proliferation of B cells
Upregulate IgE and IgG1
production by B cells
Dendritic Cells Varies Promotes DC migration Promotes DC migration
Cytokines
Suppresses IFN-γ and IL-12
production
Enhances TNF-α
production
Enhances IL-5, IL-13, and
eotaxin expression
Enhances IL-10 and IL-6
production
Antimicrobial Peptides Inhibits AMP production by
epithelial cells
Induces AMP production
by neutrophils Unknown
factor (G-CSF) [98]. In contrast, inﬂuenza infection of
mice genetically deﬁcient in COX-2 resulted in reduced
mortality, inﬂammation, and cytokine responses compared
to infection of wild-type control [99]. Peak lung viral titers
were signiﬁcantly elevated in COX-2−/− mice but returned
to levels seen in wild-type mice by day 6, suggesting a role
for COX-2 in controlling early viral replication but not in
virus clearance. Interestingly, levels of PGE2 in inﬂuenza-
infected COX-2−/− mice were equivalent to levels measured
in infected wild-type mice. The lack of PGE2 deﬁciency in
COX-2−/− mice could be due to compensatory upregulation
of COX-1 activity, as has been described before [100].
Mice infected with highly virulent H5N1 and treated
withacombinationofcelecoxib,theneuraminidaseinhibitor
zanamivir, and mesalazine (an aminosalicylate drug that
exhibits weak 5-LO and COX inhibition [101]) showed
signiﬁcantly improved survival even when treatment was
delayed 48 hours [102]. The beneﬁcial eﬀect of cele-
coxib and mesalazine likely stemmed from their eﬀects
on immunopathology, as mice treated with triple therapy
had similar viral loads as those treated with zanamivir
alone. Triple therapy signiﬁcantly reduced levels of the
proinﬂammatory cytokines IL-6, TNF-α,a n dI F N - γ.
Another group treated inﬂuenza-infected mice with
paracetamol (acetominophen), a selective inhibitor of COX-
2[ 103, 104]. Paracetamol-treated mice had improved lung
function, and reduced immunopathology compared to con-
trol mice. A separate group of mice treated with celecoxib
also showed improvements in cellular inﬁltrates, lung func-
tion and pathology. However, the degree of improvement
was generally less than that seen in paracetamol-treated
mice. In contrast to mice genetically deﬁcient in COX-2
[99],paracetamol-andcelecoxib-treatedmicehadviralloads
equivalent to those in untreated control mice. Virus-speciﬁc
CD4+ and CD8+ T cell numbers were not altered in treated
mice, and treatment with paracetamol or celecoxib did not
interfere with the establishment of protective immunity to a
second infection with a diﬀerent inﬂuenza subtype.
The signiﬁcantly increased viral titers seen in COX-2−/−
mice but not observed in mice treated with COX-2 inhibitors
could be due to a functional defect in innate immunity,
as COX products are known to be involved in modulating
the innate immune response [105]. In addition, COX-2−/−
mice have a complete loss of COX-2 activity, whereas mice
treated with inhibitors still retain some COX-2 activity due
to insuﬃcient inhibition by the drug. COX-2−/− mice had
levels of PGE2 in bronchoalveolar lavage (BAL) ﬂuid similar
to wild-type mice, suggesting that the eﬀects of COX-2
deﬁciency in this model may not be due to lack of PGE2.
As COX-2−/− deﬁciency is likely to aﬀect the production of
otherprostaglandins(suchasTXA2,PGD 2,PGF 2,andPGI 2),
it is possible that decreased levels of one of the other COX
products are responsible for increased survival.
Inﬂuenza infection upregulates 5-LO expression and/or
levels of LTs in cell lines as well as in lungs of infected mice
andhumans[106–108].However,fewstudieshaveexamined
inﬂuenza infection in the context of altered 5-LO production
(either due to genetic deﬁciency or pharmacologic inhibi-
tion). One study has reported a beneﬁcial eﬀectofexogenous
LTB4 administration during inﬂuenza infection of mice
[75]. Mice treated daily with LTB4 had signiﬁcantly reduced
lung viral loads. The lungs of LTB4-treated mice showed
increasedlevelsofmultipleantimicrobialpeptides,decreased
inﬂammatory cell inﬁltration, and partially restored lung
architecture. The antiviral eﬀect of LTB4 was mediated by
neutrophilsandthehigh-aﬃnityBLT1receptor,asviralloads
were unaﬀected in neutrophil-depleted or BLT1-deﬁcient
mice. LTB4 treatment of primary human neutrophils in this
study induced antimicrobial peptide release and decreased
inﬂuenza titers, demonstrating that the eﬀects of LTB4
on neutrophils are similar in both mice and humans.
This is in agreement with another study, in which humanMediators of Inﬂammation 5
neutrophils treated with LTB4 showed signiﬁcantly more
myeloperoxidase (MPO) activity and α-defensin production
than untreated cells, and LTB4-treated neutrophils had en-
hanced virucidal activity against inﬂuenza virus, human
coronavirus, and RSV [109]. The role of cysLTs during
inﬂuenza infection has yet to be deﬁned in detail. Enhanced
levels of cysLTs seen in COX-2−/− mice infected with
inﬂuenza are associated with increased survival [99], but
whether the decreased mortality in COX-2-deﬁcient mice is
directly due to cysLTs in this model is unknown.
The beneﬁcial eﬀects of COX-2 deﬁciency may also be
due to shunting of released AA to the 5-LO pathway. A
number of reports suggest that COX inhibitors enhance
production of LTs [110, 111]. Indeed, COX-2−/− mice
showed higher BAL ﬂuid levels of cysLTs than wild-type
mice following infection with inﬂuenza. However, in mice
treated with a combination of zanamivir, celecoxib, and
mesalazine, increased survival was associated with lower LT
levels and higher PGE2 levels in the treated mice compared
to wild type. The discrepancies in COX and 5-LO products
in these models may reﬂect the diﬀerent pathophysiology of
the inﬂuenza strains used. Perhaps increased LT production
during severe H5N1 infection promotes inﬂammation and
l o c a lt i s s u ed a m a g e ,w h i l eP G E 2 provides a balancing
protective inﬂuence. In contrast, during infection with the
less virulent H3N2 virus, enhanced LT production may
contribute to virus clearance without a detrimental eﬀect
on host inﬂammation. However, in the case of either virus
lower levels of the proinﬂammatory cytokines IL-6, TNF-α,
and IFN-γ were correlated with decreased morbidity and
increased survival. Other diﬀerences in the studies could
be accounted for by diﬀerences in virus subtype, virus
inoculum, mouse strain, or drug dose and delivery method.
However,partialCOXinhibitionbypharmacologicinterven-
tion appears to be beneﬁcial in reducing immunopathology
while still controlling viral replication during inﬂuenza
infection in mice.
4.2. Respiratory Syncytial Virus. Respiratory syncytial virus
(RSV) is the leading cause of bronchiolitis and pneumonia
in infants [112, 113]. RSV is also a signiﬁcant pathogen in
the elderly population, particularly those living in long-term
care facilities or with underlying cardiopulmonary disease
[114]. The immunocompromised are at risk for severe RSV
infection, with mortality rates of up to 80% reported for
RSV pneumonia [115]. RSV induces PGE2 release in vitro,
in animal models, and in lungs of infants with RSV bron-
chiolitis [116–119]. Treatment with COX inhibitors reduces
RSV replication in vitro and diminishes immunopathology
in vivo. Blocking PG production with NS-398, celecoxib,
or the cPLA2 inhibitor pyrrophenone reduced virus particle
production in the A549 airway epithelial cell line [116]. COX
inhibition also reduced transcription and production of the
proinﬂammatorycytokinesIL-8andRANTES(CCL5).RSV-
induced activation of interferon regulatory factor (IRF) and
NF-κB activation were suppressed by a high concentration of
celecoxib. Another study demonstrated that the nonselective
COX inhibitor indomethacin decreased lung histopathology
in RSV-infected cotton rats, but COX inhibition did not
signiﬁcantly aﬀect viral replication [117].
RSV also induces production of LTB4 and cysLTs in both
animal models and infants aﬄicted with RSV bronchiolitis
[119–125]. LT concentrations during RSV infection have
been correlated with development of symptoms and in
some reports are associated with disease severity [107, 122,
126, 127]. Treatment of RSV-infected mice with the 5-LO
inhibitor zileuton reduced inﬂammatory cell numbers in
the lung, prevented RSV-induced weight loss, and decreased
RSV-induced airway constriction [122]. Viral titers were
somewhat lower in the lungs of zileuton-treated mice,
although the diﬀerence was not statistically signiﬁcant. Even
when administered after the emergence of respiratory symp-
toms, zileuton reduced airway resistance and weight loss
compared to untreated mice. Treatment with the cysLTR1
antagonist MK-571 decreased RSV-induced airway hyperre-
activity (AHR) [121]. In contrast to treatment with zileuton,
MK-571 did not aﬀect inﬂammatory cell recruitment or
production of IL-4 and IFN-γ in RSV-infected mice. A
possible eﬀect of MK-571 on viral titers was not examined
in this study.
Similar to highly virulent inﬂuenza H5N1, successful
treatment of RSV infection may require the use of an
antiviral agent in combination with an anti-inﬂammatory
agent that limits immunopathology. In support of this,
treatment of RSV-infected cotton rats with the RSV-speciﬁc
humanized monoclonal antibody palivizumab and a glu-
c o c o r t i c o i dr e s u l t e di ne n h a n c e dc l e a r a n c eo fR S Va n d
limited lung histopathology compared to controls [128].
Further support comes from a model of pneumonia virus of
mice (PVM), a paramyxovirus that is a close phylogenetic
relative of RSV. PVM infection increased levels of cysLTs
in the lung [129]. In this model, administration of either
the cysLT1 antagonist montelukast or the nucleoside analog
ribavirin did not aﬀect disease severity. However, combined
therapyofmontelukastwithribavirinsubstantiallydecreased
morbidity and mortality of PVM-infected mice.
Administration of montelukast during primary RSV
infection prevented enhanced AHR, airway eosinophil
recruitment, and mucus overproduction upon reinfection
[120]. Montelukast administered only during secondary
infection did not aﬀect this enhanced response. Previous
studies have shown that LTs are only transiently elevated
during the acute phase of infection and that levels drop to
baseline shortly after [130]. This suggests that LT inhibitors
may have a beneﬁcial eﬀect during the early phase of
infection but may no longer be useful as treatment for the
long-term airway dysfunction observed after RSV infection
when LT levels are no longer elevated.
The above reports demonstrate a beneﬁcial eﬀect of 5-
LO product inhibitors or cysLT1 receptor antagonists during
primary infection with RSV. However, the studies in animal
models used pharmacologic agents given to mice starting on
thedaybeforeinfection,whereastreatmentinhumansistyp-
ically initiated later during the course of infection after the
emergence of symptoms. Delaying zileuton treatment until
3 days post infection, after respiratory symptoms emerged,
still reduced clinical signs during primary RSV infection in6 Mediators of Inﬂammation
mice. However, there have been conﬂicting results when 5-
LO inhibitors and cysLT antagonists were used as treatment
in children with RSV bronchiolitis. One study suggested a
beneﬁcial eﬀect of the cysLTR1 antagonist montelukast on
lung symptoms after RSV bronchiolitis [131], but further
studies have failed to corroborate these ﬁndings [132–134].
To our knowledge, there are no human studies that examine
prophylactic administration of 5-LO pathway inhibitors or
receptor antagonists to high-risk children. Further studies
are needed to deﬁne the role of LT inhibitors in patients with
primary RSV infection and in those experiencing persistent
airway dysfunction after RSV.
While many viruses are capable of causing respiratory
infections, relatively little is known about the contributions
made by eicosanoids to the pathogenesis of respiratory
viruses other than inﬂuenza and RSV. Rhinovirus (RV)
infection increases expression of 5-LO, FLAP, and COX-2
in human bronchial cells [135]. In addition, cysLT levels in
BALﬂuidareincreaseduponrhinovirusinfectioninhumans
andcorrelatewithemergenceofupperrespiratorysymptoms
[107, 135]. Adenovirus induces COX-2 expression and PGE2
release in murine ﬁbroblasts [136] and in human primary
synovial ﬁbroblasts [137]. Additional studies are necessary
to examine adenovirus-induced PG production in lung-
relevant cell types, but in vivo studies of human adenovirus
pathogenesis are limited by the strict species speciﬁcity of
adenoviruses. Using mouse adenovirus type 1 to study the
pathogenesis of adenovirus respiratory infection [138]w i l l
provide a useful tool to deﬁne the roles of eicosanoids to
adenovirus respiratory infection.
Human cytomegalovirus (HCMV) can also cause respi-
ratory infections, although symptomatic disease is uncom-
mon in immunocompetent individuals [139]. HCMV
induces 5-LO expression and LTB4 production [140]i n
vascular smooth muscle cells as well as COX-2 expression
and PGE2 production in ﬁbroblasts [141]. COX-2 inhibition
reduces levels of the immediate-early 2 mRNA and protein
in addition to viral DNA replication and transcription
of some early and late mRNAs. Treatment of HCMV-
infected ﬁbroblasts with COX inhibitors inhibits cell-to-cell
spread of virus [142]. Of note, while many reports with
other viruses have shown inhibition of viral replication or
gene transcription by COX inhibitors at non-physiologic
concentrations, these results with HCMV were obtained
with concentrations of COX inhibitors that are achievable
in human plasma. Although few studies have examined the
eﬀect of 5-LO products on HCMV pathogenesis, one study
reported that exogenous LTB4 inhibited reactivation of CMV
following allogeneic bone marrow transplantation (BMT) in
m i c e ,d e m o n s t r a t i n gab e n e ﬁ c i a le ﬀect for this LT [143].
5. Common Themes
Fromthe datasummarized above(seealsoTable 2),it is clear
that the eﬀect of COX or 5-LO inhibition or antagonism of
cysLT receptors on host responses to respiratory viral infec-
tion is variable and in some cases may be pathogen- and/or
model-speciﬁc. In general, COX inhibition or deﬁciency is
associated with less exuberant inﬂammation and in some
cases improved survival. COX products may play a role in
controlling early viral replication, although this possible role
is only evident for inﬂuenza infection in mice completely
lacking COX-2 activity and not in mice treated with a
COX-2 inhibitor. These data are consistent with the role of
PGE2 as an immunomodulatory mediator, balancing pro-
inﬂammatory actions with suppressive eﬀects on innate and
adaptive immune function. Inhibition of LT production or
signaling during respiratory viral infection is associated with
less inﬂammation accompanied by variable (but generally
beneﬁcial) eﬀects on lung physiology. However, administra-
tion of exogenous LTB4 also blunted inﬂammatory responses
to inﬂuenza virus in one study [75], suggesting that various
5-LO products may be diﬀerentially involved in promoting
inﬂammation and aﬀecting host immune responses to viral
infection.
6. Therapeutic Implications
Respiratory viral infections cause substantial disease and
are associated with signiﬁcant morbidity, mortality, and
healthcare utilization. Many antiviral drugs are available to
treat infection with human immunodeﬁciency virus, and a
smaller number of drugs such as acyclovir and ganciclovir
are available to treat infections with herpesviruses such as
herpes simplex virus, varicella zoster virus, and HCMV. In
contrast, far fewer drugs are available to treat viruses that
most frequently cause respiratory infections. Neuraminidase
inhibitors such as oseltamivir and zanamavir can be used
as prophylaxis to prevent infection by inﬂuenza virus or
used to treat infection. Older drugs such as amantadine and
rimantadine can also be used to prevent or treat inﬂuenza.
However, the emergence of drug-resistant inﬂuenza strains
has the potential to increasingly limit the utility of these
drugs. The nucleoside analog cidofovir has been used to treat
adenovirus infections, although it has substantial toxicities
and no randomized clinical trials have been performed to
show clinical beneﬁt. Currently, there are no drugs that
have consistently been shown to be safe and eﬀective for
the treatment of disease caused by infection with RSV,
rhinovirus, human metapneumovirus, or other viruses that
commonly cause respiratory infections.
Preventing virus-induced inﬂammation may serve as an
important adjunct to any antiviral therapy. When antivi-
ral drugs are not available, modulation of virus-induced
inﬂammation by itself may serve as an eﬀective strategy
to treat disease caused by viruses. Drugs with the ability
to modulate eicosanoid production, such as ibuprofen and
acetaminophen, are already frequently used in patients
with respiratory infections to alleviate fevers, myalgias,
and nonspeciﬁc symptoms. Studies described above that
show decreased virus-induced inﬂammation and increased
survival in animals treated with an inhibitor of PG or LT
synthesis or in PG- or LT-deﬁcient animals support the
potential beneﬁt of this approach. Drugs that modulate
eicosanoid production may be particularly useful to prevent
or treat infections in patients with exaggerated eicosanoid
production at baseline. For instance, exaggerated PGE2
production in the setting of bone marrow transplantationMediators of Inﬂammation 7
Table 2: Eﬀects of PGE2 and Leukotrienes on respiratory syncytial virus and inﬂuenza infection.
PGE2 Leukotrienes
COX Inhibition COX-2 Deﬁciency
Reduction in viral replication in
vitro
Reduction in pulmonary
inﬂammatory, weight loss, and
RSV-induced airway constriction in
mice treated with 5-LO inhibitor RSV Suppression of virus-induced
cytokine production in vitro
No eﬀect on viral replication in the
lungs in vivo
CysLTR1 antagonism during primary
infection prevents enhanced AHR
upon reinfection
Decreased lung pathology in vivo
Decreased RSV-induced AHR but no
eﬀect on cytokine production in mice
treated with cysLTR1 antagonist
No eﬀect on viral replication or
disease severity in micetreated with
celecoxib
Decreased mortality, pulmonary
inﬂammation and cytokine
responses in COX-2−/− mice
Reduced lung viral loads and
decreased pulmonary inﬂammatory in
mice treated with exogenous LTB4
Inﬂuenza
Suppression of virus-induced
cytokine production in mice treated
with celecoxib
Increased viral titers in lungs of
COX-2−/− mice compared to
controls Improved survival and reduced
proinﬂammatory cytokine levels in
mice treated with zanamivir,
celecoxib, and mesalazine
Improved lung function and
reduced immunopathology in mice
treated with paracetamol
has been associated with increased susceptibility to bac-
terial infection that is linked to impaired neutrophil and
macrophage phagocytosis and killing [144, 145]. Increased
PGE2 productionhasbeenreportedinhumanswithavariety
of disease states including cancer [146], aging [147], HIV
infection [148], malnutrition [149, 150], and stem cell and
solid organ transplant recipients [151, 152], making the
potential beneﬁts of this approach more widespread.
Any therapy that involves modulation of eicosanoid pro-
duction must consider the potential for deleterious eﬀectson
the development of adaptive immunity and subsequent pro-
tection from secondary infection. PGE2 plays an important
role in optimal antibody synthesis, as COX inhibitors reduce
antibody production in activated human B lymphocytes [48,
49].Inaddition,micegeneticallydeﬁcientinCOX-2produce
signiﬁcantly less IgM and IgG than wild-type mice [48].
There is evidence that COX-2 plays a role in potentiating
antibody production in humans as well. Human volunteers
challenged with RV showed increased nasal symptoms
and a suppressed serum neutralizing antibody response
when treated with aspirin or acetaminophen, suggesting a
protective role for COX products in reducing symptoms and
promotinganantibodyresponse[153].Onelarge-scalestudy
has been performed in which children were administered
prophylactic paracetamol when receiving routine childhood
vaccinations [154]. Antibody responses to several of the
vaccine antigens were less robust in patients receiving
prophylactic paracetamol. Evidence also exists that LTs, like
PGE2, promote appropriate antibody responses [79–81, 87],
but the eﬀect of 5-LO inhibitors and receptor antagonists on
antibody production has not yet been described.
7. Conclusions
Eicosanoids modulate many host immune responses that
are important contributors to viral pathogenesis. It will
be essential to better deﬁne mechanisms underlying the
eﬀects of eicosanoids on both innate and adaptive immune
responses to respiratory viral infection in order to develop
therapies with maximal anti-inﬂammatory beneﬁt and min-
imal impact on protective immune responses. For instance,
the use of speciﬁc receptor agonists or antagonists may
eventually provide a better-tailored approach than inhibitors
of PG or LT synthesis to treat patients with respiratory
viral infections. In general terms, however, alteration of
eicosanoid production or antagonism of eicosanoid recep-
tors has the potential to serve as a useful treatment strategy
for respiratory viral infections.
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